Skip to Content
COVID-19 Resources
Developmental Therapeutics Program (DTP)
Contact DTP
Show menu
Search this site
Last Updated: 7/21/2020

Tumor Repositories:

DCTD/DTP Tumor Repository (catalog for download)
Contact: DCTD Tumor Repository: DCTDTumorRepository@nih.gov

PLEASE NOTE: The DCTD Tumor Repository is now accepting new sample request and has resumed normal operations.

DTP has maintained since the early 1960s a low temperature repository of transplantable in vivo-derived tumors and in vitro-established tumor cell lines from various species, located at the National Cancer Institute in Frederick, Maryland. This tumor Repository serves as a resource for viable, contaminant-free experimental tumor lines, many of which are not obtainable elsewhere. The Repository makes these materials available to qualified investigators as a service to the cancer research community.

 

NCI Patient Derived Models Repository (PDMR)
Contact: Dr. Yvonne A. Evrard: NCI_PDM_Repository@mail.nih.gov

PLEASE NOTE: The PDMR Repository is accepting new sample requests and has resumed normal operations.

The National Cancer Institute’s Patient-Derived Models Repository (NCI PDMR) is a repository of low passage patient-derived xenografts (PDXs), tumor cell cultures (PDCs), organoids (PDOrg), and cancer associated fibroblasts (CAFs) available to investigators at both non-profit and for-profit institutions for a modest cost. The PDMR generates models from solid tumor histologies with a focus on complimenting existing publicly available models and filling in gaps where needed, for instance creating models for rare cancers (e.g., mesothelioma, Merkel cell carcinoma, osteosarcoma, salivary gland cancer, and others). Available models include clinical history and molecular characterization information so investigators can select models best fit to their research. Researchers not interested in performing wet lab studies can mine the metadata associated with the models using the NCI PDMR database.

About the Branch Chief

Dr. Melinda Hollingshead has served as Chief of the Biological Testing Branch at NCI since 2005. The Biological Testing Branch (BTB) establishes patient derived xenograft (PDX) models, isolates cell lines from PDX models and conducts preclinical anti-cancer drug evaluations in relevant rodent models. Additionally, the BTB manages the distribution of cell lines and tumor samples from the DCTD Repository. More…